Table 2.

Best Response, PFS and OS According to Neutropenia Grade

	Overall (N=31)	FOLFOX (N=11)	FOLFIRI (N=20)	P
Stable disease	4 (12.9%)	1 (9.1%)	3 (15%)	0.35
Progression of disease	20 (64.5%)	10 (90.9%)	10 (50%)
Not evaluated	7 (22.6%)	0	7 (35%)
PFS M-months (95%CI)	3 (3–4)	2 (2–4)	3 (3-NR)	0.14
OS M-months 95%CI  All patients  Patients with PFS >3 months with NabGem	8 (5–10) 8 (4–8)	5 (2–10) 2 (2-NR)	9 (7–17) 9 (7–17)	0.01* 0.02*

Note: *statistically significant.

Abbreviations: M, median; PFS, progression free survival; OS, overall survival; NR, not reached).